{"id":"NCT03129100","sponsor":"Eli Lilly and Company","briefTitle":"A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis","officialTitle":"A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-09","primaryCompletion":"2020-05-26","completion":"2021-05-27","firstPosted":"2017-04-26","resultsPosted":"2021-06-18","lastUpdate":"2022-06-13"},"enrollment":773,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Axial Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ixekizumab (IXE) 80Q4W","type":"EXPERIMENTAL"},{"label":"Ixekizumab (IXE) 80Q2W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.","primaryOutcome":{"measure":"Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)","timeFrame":"Week 64","effectByArm":[{"arm":"Combined IXE","deltaMin":83.3,"sd":null},{"arm":"Placebo","deltaMin":54.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":127,"countries":["United States","Argentina","Austria","Brazil","Canada","Czechia","Finland","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["36792107","35853675"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/4AAJNNvqrukMW8Go2I28OI"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":348},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Iridocyclitis","Arthralgia","Pharyngitis"]}}